Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions: Driving Decision Aid, Older Drivers Website; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 529 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: La Jolla, California • Aurora, Colorado • Indianapolis, Indiana

Conditions: Diabetic Macular Edema
Interventions: Iluvien 0.19 MG Drug Implant, Aflibercept; Drug
Lead sponsor: Alimera Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 36 more

Conditions: Central Retinal Vein Occlusion
Interventions: Ranibizumab; Drug
Lead sponsor: California Retina Consultants; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more

Conditions: Diabetic Retinopathy, Macular Degeneration, Vision, Subnormal
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Interventions: 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept; Biological
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more

Conditions: RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Interventions: Crizanlizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 25 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Diabetic Macular Edema
Interventions: Macugen® pegaptanib sodium; Drug
Lead sponsor: Valley Retina Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: McAllen, Texas

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab, Conventional Laser for ROP; Drug · Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 4 Weeks to 22 Weeks
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 15
States / cities: Pasadena, California • Denver, Colorado • Peoria, Illinois + 7 more

Conditions: Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
Interventions: LFG316, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Tucson, Arizona • Torrance, California • Fort Myers, Florida + 4 more

Conditions: Microvascular Disease, Retinal Disease
Interventions: XyCAM CRE Imaging; Device
Lead sponsor: Stuart Terry Eye Associates; Other
Eligibility: 21 Years to 100 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
Interventions: IRX-101, Control; Drug
Lead sponsor: iRenix Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Diabetic Retinopathy
Interventions: Aflibercept Injection; Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Beverly Hills, California • Orlando, Florida • Winter Haven, Florida + 10 more

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 48
States / cities: Irvine, California • Loma Linda, California • Palm Springs, California + 39 more

Conditions: Retinal Pigment Epithelial Detachment
Interventions: Ranibizumab; Drug
Lead sponsor: Clement K. Chan; Other
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Los Angeles, California • Palm Desert, California • Rapid City, South Dakota

Conditions: Central Retinal Vein Occlusion
Interventions: fluocinolone acetonide (Retisert Implant, Bausch and Lomb); Device
Lead sponsor: Glenn Jaffe; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetic Retinopathy
Interventions: Surabgene Lomparvovec, Sham, Topical Steroid, Artificial Tears; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 39
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 36 more

Conditions: Moderate Non-proliferative Diabetic Retinopathy
Interventions: Alpha Lipoic Acid; Dietary Supplement
Lead sponsor: Ferris State University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Big Rapids, Michigan • Grand Rapids, Michigan

Conditions: Retinal Vein Occlusion
Interventions: Ranibizumab (Lucentis ); Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: Not listed
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 81
States / cities: Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Vision Research Foundation; Other
Eligibility: 30 Weeks to 36 Weeks
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Los Angeles, California • Menlo Park, California • Miami, Florida + 6 more

Conditions: Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 57
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Uveitis, Vasculitis, Ocular Inflammatory Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy
Interventions: Fenofibrate, Placebo; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 80 Years
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 66
States / cities: Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more

Search by objective public record fields.

Advancing Understanding of Transportation Options

A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

Lucentis for Central Retinal Vein Occlusion (CRVO)

Diabetic Retinopathy and Visual Function Study

ADVM-022 Intravitreal Gene Therapy for DME

Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Collecting Data on Retinal Blood Blood Flow and Blood Vessel Shape/Appearance Using an Investigational Device, XyCAM CRE, and to Then Compare Those Images With Images Collected From a Patient's Routine Clinical Examination.

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

Evaluation of Vitrectomy for Diabetic Macular Edema

Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy

Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease

Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema

Fenofibrate for Prevention of DR Worsening